Results 111 to 120 of about 378,540 (249)
Pediatric Dermatology, Volume 43, Issue 4, Page 996-998, July/August 2026.ABSTRACT A 16‐year‐old girl presenting with calcinosis cutis and localized scleroderma subsequently developed delayed‐onset idiopathic inflammatory myopathy five years after initial skin involvement. Despite the absence of typical dermatomyositis features and negative myositis‐specific antibodies, whole‐body MRI revealed extensive subclinical muscle ...
Edoardo Marrani +5 more
wiley +1 more source
Clinical and Translational Allergy, Volume 16, Issue 6, June 2026.This review positions skin tape stripping as a methodological bridge in atopic dermatitis, linking epidermal molecular profiling with systemic inflammation. Integrated with multi‐omics technologies, STS enables non‐invasive biomarker discovery, disease endotyping, and treatment monitoring, advancing precision medicine for AD. ABSTRACT Atopic dermatitis
Ziyuan Tian, Ke Xue, Yong Cui
wiley +1 more source
Muscle MRI at the time of questionable disease flares in Juvenile Dermatomyositis (JDM)
Pediatric Rheumatology Online Journal, 2017 Background The course of JDM has improved substantially over the last 70 years with early and aggressive treatments. Yet it remains difficult to detect disease flares as symptoms may be mild; signs of rash and muscle weakness vary widely and are often ...
Rabheh Abdul-Aziz +6 more
doaj +1 more source
La Pediatria medica e chirurgica : Medical and surgical pediatrics, 1990 Juvenile dermatomyositis (JDM) is a chronic multisystem inflammatory disease that primarily involves skin and muscles. The clinical picture is mainly characterized by the typical cutaneous rash and by skeletal muscle weakness. Nevertheless the vasculitic process may extend in some cases to other organs such as lung, joints or gastrointestinal system ...
MARTINI, ALBERTO +3 more
openaire +2 more sources
Pediatric Pulmonology, Volume 61, Issue 6, June 2026.ABSTRACT Background In the InPedILD trial, nintedanib had an acceptable safety profile in children and adolescents (aged 6−17 years) with fibrosing ILDs. The open‐label extension of the InPedILD trial, InPedILD‐ON, is assessing the longer‐term safety of nintedanib in these patients. Methods Patients who completed the InPedILD trial on treatment and had
Robin Deterding +14 more
wiley +1 more source
Spotlight: What's New in JEADV – Editor‐in‐Chief's Selection
JEADV Clinical Practice, Volume 5, Issue 2, Page 367-372, June 2026.
Carle Paul
wiley +1 more source
Atypical presentation of anti-NXP-2 positive juvenile dermatomyositis
Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2023 Dear Editor, The anti-NXP-2 is one of a myositis-specific autoantibody considered a marker of dermatomyositis (DM)1,2. In addition, there is a strong relationship between NXP-2 autoantibodies and calcinosis, particularly in juvenile DM2.
Andreia Coimbra-Sousa +3 more
doaj
Juvenile Dermatomyositis with Generalized Edema
Pediatric Neurology Briefs, 2001 A 7-year-old girl presenting with an 8-week history of fatigue, myalgia, dyspnea, and generalized, nonpitting edema of the extremities, face, chest, and abdomen, is reported from the Walter Reed Army Medical Center, Washington, DC.
J Gordon Millichap
doaj +1 more source
Unmet social needs in pediatric rheumatic disease: a study of disparities
Pediatric Rheumatology Online JournalBackground and Objective Children with rheumatic diseases experience social determinants of health that influence access to care and outcomes, yet data in pediatric rheumatology are limited. We aimed to characterize caregiver-reported social determinants
Kristina Ciaglia +3 more
doaj +1 more source
Juvenile dermatomyositis in Latvia: clinical, radiologic, laboratory, and therapeutic findings from 2010 to 2025 [PDF]
Lilija Banceviča +3 more
openalex +1 more source